Michael Trejeeve Martyn

Dr. Michael Trejeeve Martyn


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
KFKathleen D. Faulkenberg
Kathleen D. Faulkenberg
CAChonyang Albert
Chonyang Albert
ZIZachary J. Il'GIovine
Zachary J. Il'GIovine
VRVarinder K. Randhawa
Varinder K. Randhawa
RSRandall Starling
Randall Starling

6 December 2022 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
ARAndres Carmona Rubio
Andres Carmona Rubio
JEJerry D. Estep
Jerry D. Estep
MHMazen Hanna
Mazen Hanna
Despite the rapid expansion of noninvasive (nonbiopsy) diagnosis, contemporary patients with cardiac amyloidosis too often present with advanced features of disease, such as diminished quality of life, elevated natriuretic peptides, and advanced heart failure. Therapeutics for transthyretin cardiomyopathy (ATTR-CM) are most effective when administered before significant symptoms of cardiac dysfunction manifest, making early identification of affected individuals of paramount importance. Community engagement and ensuring that a broad range of clinicians have working knowledge of how to screen for ATTR-CM in everyday practice will be an important step in moving disease identification further upstream. However, reliance on the appropriate and timely diagnosis by individual clinicians may continue to underperform. This review highlights how targeted screening of special populations may facilitate earlier diagnosis. Systems of care that operationalize screening of high-risk subpopulations and prospective validation of novel approaches to ATTR-CM identification are needed.

5 April 2023 in Current Treatment Options in Cardiovascular Medicine
Verified
Journal Article
Closed access
PDF file
JBJeremy A. Brooksbank
Jeremy A. Brooksbank
KFKathleen D. Faulkenberg
Kathleen D. Faulkenberg
WTW. H. Wilson Tang
W. H. Wilson Tang
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn

14 July 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
JSJoshua Saef
Joshua Saef
MHMuzna Hussain
Muzna Hussain
LILauren Ives
Lauren Ives
AKAlan Kiang
Alan Kiang
WJwael A. A jaber
wael A. A jaber

23 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJoshua Saef
Joshua Saef
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
ADAnusha Ray Dey
Anusha Ray Dey
RKRola Khedraki
Rola Khedraki
LILauren Ives
Lauren Ives
WTW.H. Wilson Tang
W.H. Wilson Tang
Background: Transthyretin cardiac amyloidosis (ATTR-CM) is classically thought of as a progressive disease with preserved systolic function. The longitudinal clinical trajectories of ATTR-CM with impaired left ventricular ejection fraction (LVEF) remain unclear. Methods: This is a single-center retrospective cohort study of consecutive patients with ATTR-CM who underwent two or more echocardiograms with baseline LVEF < 50%. Patients were stratified according to the presence of ≥5% change in LVEF. A Cox proportional hazard model examined hazard of a composite outcome of death, transplant, or LVAD insertion over the two years following diagnosis. Results: In our study cohort of 179 patients, 62 patients (34.6%) experienced an increase in LVEF while 33 (18.4%) experienced a decrease in LVEF. After adjusting for covariates, patients with a decrease in EF experienced increased hazard of death (HR 2.15, 95% CI 1.05–4.40, p = 0.038) compared to those with stable or an increase in LVEF. Changes in LVEF corresponded with significant differences in NT proBNP trajectories, but initial biomarker levels or clinical staging were not predictive of LVEF trajectory. Conclusions: in ATTR-CM patients with impaired LVEF, over a third demonstrated improved LVEF over time, while those with a decrease in LVEF had worse long-term outcomes.

15 November 2024 in JACC: Heart Failure
Verified
Journal Article
Closed access
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
HPHarsh Patolia
Harsh Patolia
NPNicholas Platek
Nicholas Platek
RTRyan Tang
Ryan Tang
NANancy M. Albert
Nancy M. Albert
JHJessica Hohman
Jessica Hohman